Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

The TJX Companies, Inc. Reports Q2 FY26 Results; Comp Sales Growth of 4%, Pretax Profit Margin of 11.4%, and Diluted EPS of $1.10 All Above Plan; Raises FY26 Pretax Profit Margin and EPS Guidance

FRAMINGHAM, Mass.--(BUSINESS WIRE)--The TJX Companies, Inc. (NYSE: TJX), the leading off-price apparel and home fashions retailer in the U.S. and worldwide, today announced sales and operating resu...

How does TJX's Q2 FY26 performance compare to its peers in the off‑price retail sector and what implications does this have for market share? What are the drivers behind the 4% comparable sales growth and can they be sustained in the upcoming quarters? How will the raised FY26 pretax profit margin and EPS guidance affect TJX's valuation and target price?
Symbol: TJX
Earnings
22 days ago
Read more businesswire

Knight Announces Normal Course Issuer Bid

MONTREAL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by ...

How does the size and timing of this NCIB compare to recent buyback programs by peer companies in the specialty pharma sector? What is the expected impact of the buyback on earnings per share (EPS) and valuation multiples? How will the NCIB affect Knight Therapeutics' share liquidity and price volatility over the next 12 months?
Symbol: GUD
Buyback
22 days ago
Read more globenewswire

Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales Jazz obtains exclusive worldwide rights ...

How does this exclusive licensing deal compare to Jazz's previous collaborations in terms of upside potential and risk exposure, and what could it mean for the company's long‑term growth trajectory? What are the expected timelines for SAN2355's development milestones and potential regulatory approvals, and how might those dates influence the stock's valuation? How will the $42.5 million upfront payment and potential milestone payments affect Jazz Pharmaceuticals' cash flow and earnings guidance?
Symbol: JAZ
Licensing
22 days ago
Read more prnewswire